NEW DELHI, June 22 (Xinhua) — India's vaccine maker Bharat Biotech's Covaxin has shown 77.8 percent efficacy in phase III trials, multiple local media reported on Tuesday.
"Bharat Bookool waa 77.8 boqolkiiba oo wax ku ool ah oo ka hortagaya Qalin-19, sida laga soo xigtay xogta laga soo xigtay tijaabooyinka Wajiga ee Wajiga oo lagu sameeyay 25,800 ka-qaybgale oo ku yaal India," ayaa lagu yiri warbixin.
Heerka wax ku oolka ah ayaa soo baxay Talaadadii ka dib markii dawooyinku ka hor imaatinka guddiga khasabka guud ee India (DCGI) ee ku-khasabka ah (sek) ayaa la kulmay oo ka wada hadlay natiijooyinka.
Shirkadda dawooyinka ayaa soo gudbisay xogta maxkamadda ee maxkamad ee Wajiga tallaalka ee loo yaqaan 'DCGI' DCGI dhammaadka usbuuca dhammaadka.
Wararka ayaa sheegaya in shirkadda la filayo inuu ku yeesho kulan "horay loo soo gudbiyay 'oo ay la yeelatay maamulka Ururka Caafimaadka Adduunka Arbacadii, si ay uga wada hadlaan tilmaamaha ugu dambeysa ee macluumaadka iyo dukumiintiyada loo baahan yahay.
Hindiya waxay bilawday tallaalka ballaaran ee ka dhan ah Qalin-19 Jan. 16 iyadoo la maareynayo laba talaal oo laga sameeyay oo ah 'Indiyaasel' iyo Covaxin.
Machadka Serum ee India (Sii) wuxuu soosaaraa Cilmiga Jaamacadda Agazeleca-Oxford, halka Bharat Biotech uu iskaashi la yeeshay Golaha Daraasad Caafimaad (ICMR) ee waxsoosaarka loo yaqaan 'Covaxan'.
Tallaalka Sputnik-ka Sputnik-ka Ruushka ayaa sidoo kale dalka ku soo duulay. Entitim
Waqtiga Post: Jun-25-2021